Orphacol ruling bolsters EU orphan exclusivity rules
This article was originally published in SRA
Executive Summary
Another European court ruling has confirmed the important role of the EU orphan drug regulation in encouraging companies to conduct R&D into medicines for rare diseases, and helped to clarify the rules regarding the orphan market exclusivity period.